Lilly vs Pfizer: Obesity Race Reaches Market Highs
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Understanding the differences between value and growth investing is essential. Learn how to choose the right approach for your goals.
24,909 articlesLilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Four high-profile tech names have shed 23% to 37% in 2026 as the Nasdaq edges higher. Analysts see substantial upside...
In uncertain times, reliable income matters. Learn why wide-moat dividend stocks hold steady, using Coca-Cola and Joh...
CrowdStrike holds steady Wednesday in early trading after strong quarterly results, while GitLab slides on a dimmer g...
Two tech giants pull back in divergent fashion. This report analyzes valuations, AI upside, and cash flow to help ret...
Jim Cramer declares Broadcom undervalued after a solid earnings quarter with AI revenue accelerating; investors weigh...
Investors are increasingly circling a single dominant payments network that could redefine how money moves worldwide,...
Wondering how your retirement savings stack up? This guide breaks down this average 401(K) balance by age, explains w...
In July, investors are weighing recession risks against reliable income. This guide highlights three dividend staples...
Chipotle and Wingstop diverged sharply this year, with Chipotle facing softer traffic and Wingstop leveraging its fra...
AI-driven investment has become a major growth engine for the U.S. economy, but a slowdown could ripple across jobs, ...
As markets shift in 2026, dividend-focused funds regain attention. This guide breaks down the ishares core high divid...